NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

危急性肢體缺血:開發中產品分析

Critical Limb Ischemia (Cardiovascular) - Drugs In Development, 2021

出版商 Global Markets Direct 商品編碼 219779
出版日期 內容資訊 英文 163 Pages
訂單完成後即時交付
價格
危急性肢體缺血:開發中產品分析 Critical Limb Ischemia (Cardiovascular) - Drugs In Development, 2021
出版日期: 2021年08月30日內容資訊: 英文 163 Pages
簡介

所謂危急性肢體缺血是週邊動脈疾病(PAD)中最危及生命的症狀。一般是由於動脈粥狀硬化性心血管疾病相關的慢性發炎過程所造成。主要的症狀有腳·腳尖的疼痛和發麻、潰爛、皮膚感染疾病等,無論是何者在發症後都無法治療。這個疾病的治療目的在於減輕危及冠狀動脈的風險要素(禁煙、減輕膽固醇等)、減輕疼痛、治癒潰瘍、避免截肢手術、改善生活品質、提升生存率等。

本報告提供全球各國治療危急性肢體缺血(CLI)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

危急性肢體缺血 - 概要

危急性肢體缺血 - 治療藥的開發

  • 開發平台概要
  • 各企業的開發平台趨勢
  • 各大學·研究機關的開發平台趨勢
  • 企業開發中的產品
  • 大學·研究機關開發中的產品

危急性肢體缺血 - 治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

危急性肢體缺血的開發治療藥的企業

  • AnGes MG Inc
  • apceth Biopharma GmbH
  • Athersys Inc
  • BiogenCell Ltd
  • Caladrius Biosciences Inc
  • Cynata Therapeutics Ltd
  • Hemostemix Ltd
  • Histocell SL
  • ID Pharma Co Ltd
  • Integene International Holdings LLC
  • Juventas Therapeutics Inc
  • Kasiak Research Pvt Ltd
  • Kowa Company Ltd
  • Neurofx Inc
  • Pharmicell Co Ltd
  • Pluristem Therapeutics Inc
  • ReNeuron Group Plc
  • Symic Biomedical Inc
  • TikoMed AB
  • U.S. Stem Cell Inc
  • Vericel Corp
  • VESSL Therapeutics Ltd
  • ViroMed Co Ltd

藥物簡介

危急性肢體缺血 - 暫停中的計劃

危急性肢體缺血 - 開發中止的產品

危急性肢體缺血 - 產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC13063IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia - Drugs In Development, 2021, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape.Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 13, 3, 2, 10 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Critical Limb Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Critical Limb Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Critical Limb Ischemia (Cardiovascular)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Critical Limb Ischemia (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Critical Limb Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Critical Limb Ischemia - Overview
  • Critical Limb Ischemia - Therapeutics Development
  • Critical Limb Ischemia - Therapeutics Assessment
  • Critical Limb Ischemia - Companies Involved in Therapeutics Development
  • Critical Limb Ischemia - Drug Profiles
  • Critical Limb Ischemia - Dormant Projects
  • Critical Limb Ischemia - Discontinued Products
  • Critical Limb Ischemia - Product Development Milestonesh
  • Appendix

List of Tables

List of Tables

  • Number of Products under Development for Critical Limb Ischemia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Critical Limb Ischemia - Pipeline by Ambulero Inc, 2021
  • Critical Limb Ischemia - Pipeline by Anaeropharma Science Inc, 2021
  • Critical Limb Ischemia - Pipeline by Antidote Therapeutics Inc, 2021
  • Critical Limb Ischemia - Pipeline by Athersys Inc, 2021
  • Critical Limb Ischemia - Pipeline by Caladrius Biosciences Inc, 2021
  • Critical Limb Ischemia - Pipeline by Constant Therapeutics LLC, 2021
  • Critical Limb Ischemia - Pipeline by Cynata Therapeutics Ltd, 2021
  • Critical Limb Ischemia - Pipeline by GPCR Therapeutics Inc, 2021
  • Critical Limb Ischemia - Pipeline by Gurus BioPharm, 2021
  • Critical Limb Ischemia - Pipeline by Helixmith Co Ltd, 2021
  • Critical Limb Ischemia - Pipeline by Hemostemix Inc, 2021
  • Critical Limb Ischemia - Pipeline by ID Pharma Co Ltd, 2021
  • Critical Limb Ischemia - Pipeline by Ixaka Ltd, 2021
  • Critical Limb Ischemia - Pipeline by Juventas Therapeutics Inc, 2021
  • Critical Limb Ischemia - Pipeline by Libella Gene Therapeutics, 2021
  • Critical Limb Ischemia - Pipeline by LifeCells LLC, 2021
  • Critical Limb Ischemia - Pipeline by New B Innovation Ltd, 2021
  • Critical Limb Ischemia - Dormant Projects, 2021
  • Critical Limb Ischemia - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Critical Limb Ischemia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021